HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $70
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $50 to $70.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $50 to $70.
